Core Viewpoint - The company has established a strategic partnership with Crescent Biopharma to jointly develop and commercialize cancer treatment methods, including novel combination therapies [1][2]. Group 1: Partnership Details - The collaboration involves the company's antibody-drug conjugate (ADC) SKB105, which targets integrin β6, and Crescent's bispecific antibody CR-001, which targets PD-1 and VEGF [1]. - Both candidate drugs are being developed for the treatment of solid tumors, with clinical trials for monotherapy expected to begin in Q1 2026 [1]. Group 2: Rights and Financial Terms - The company grants Crescent exclusive rights to research, develop, manufacture, and commercialize SKB105 outside of the Greater China region, while Crescent grants the company exclusive rights for CR-001 in the Greater China region [2]. - The financial terms include an upfront payment of $80 million from the company to Crescent, potential milestone payments of up to $1.25 billion, and tiered royalties based on SKB105's net sales [2]. - Conversely, Crescent will pay the company an upfront payment of $20 million and potential milestone payments of up to $30 million, along with tiered royalties based on CR-001's net sales [2]. Group 3: Strategic Benefits - The board believes the partnership aligns with the best interests of the company and its shareholders, enhancing the differentiated oncology pipeline and advancing the global development of SKB105 [3]. - The collaboration aims to leverage both parties' resources to explore new monotherapy and combination therapy strategies in cancer treatment, maximizing the therapeutic potential of both candidate drugs in China and globally [3].
科伦博泰生物-B(06990)与Crescent Biopharma建立战略合作伙伴关系，共同开发和商业化肿瘤治疗手段